US · Healthcare · Biotechnology
EPS came in at -0.09 against a street estimate of -0.25 — a beat of 64.0%.
Analysts rate Marker Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $7.87.
| Fund | Stake |
|---|---|
| NEA Management Company, LLC | 9.75% |
| Blue Owl Capital Holdings LP | 3.32% |
| Vanguard Capital Management, LLC | 2.56% |
| Aisling Capital Management LP | 1.95% |
| Renaissance Technologies Corp | 1.50% |
| Geode Capital Management, LLC | 0.84% |
| Advisor Group Holdings, Inc. | 0.68% |
| Vanguard Fiduciary Trust Co | 0.52% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Marker Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.